The knockdown of NLRP4, the administration of MitoQ, and the use of the autophagy inhibitor CQ all contributed to the enhanced inhibitory effect of olaparib on the proliferation of pancreatic cancer cells (Fig. 7i–l). The gene discussed is NLRP4; the disease is pancreatic neoplasm.